A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma

Autor: Eric Spierings, Jhf Falkenburg, Marie-Jose Kersten, Ruud Doorn, Hanny Fredrix, Rimke Oostvogels, Laurens E. Franssen, Kasper Westinga, Nicolaas Schaap, H M Lokhorst, Harry Dolstra, Mieke W H Roeven, T. Mutis, Ineke Slaper-Cortenbach, N W C J van de Donk, Willemijn Hobo, Michel G.D. Kester

Publikováno v: Bone Marrow Transplantation, 52, 10, pp. 1378-1383
Bone Marrow Transplantation, 52(10), 1378-1383. Nature Publishing Group
Bone Marrow Transplantation, 52(10), 1378-1383
Bone marrow transplantation, 52(10), 1378-1383. Nature Publishing Group
Franssen, L E, Roeven, M W H, Hobo, W, Doorn, R, Oostvogels, R, Falkenburg, J H F, Van De Donk, N W, Kester, M G D, Fredrix, H, Westinga, K, Slaper-Cortenbach, I, Spierings, E, Kersten, M J, Dolstra, H, Mutis, T, Schaap, N & Lokhorst, H M 2017, ' A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma ', Bone Marrow Transplantation, vol. 52, no. 10, pp. 1378-1383 . https://doi.org/10.1038/bmt.2017.118
Bone Marrow Transplantation, 52, 1378-1383

Contains fulltext : 182504.pdf (Publisher’s version ) (Closed access) Allogeneic stem cell transplantation (allo-SCT) with or without donor lymphocyte infusions (DLI) is the only curative option for several hematological malignancies. Unfortunately

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd0e9232ac989495b3e6a7c246522fff
https://hdl.handle.net/2066/182504

Towards effective and safe immunotherapy after allogeneic stem cell transplantation

Autor: Robbert M. Spaapen, m. van elk, Arjan Buijs, H M Lokhorst, Barbara Giovannone, Monique C. Minnema, Arnon P. Kater, Rimke Oostvogels, Marieke Griffioen, Eric Spierings, G.D. te Raa, D. van Baarle, Tuna Mutis

Publikováno v: Oostvogels, R, Minnema, M C, Van Elk, M, Spaapen, R M, Te Raa, G D, Giovannone, B, Buijs, A, Van Baarle, D, Kater, A P, Griffioen, M, Spierings, E, Lokhorst, H M & Mutis, T 2013, ' Towards effective and safe immunotherapy after allogeneic stem cell transplantation : Identification of hematopoietic-specific minor histocompatibility antigen UTA2-1 ', Leukemia, vol. 27, no. 3, pp. 642-649 . https://doi.org/10.1038/leu.2012.277
Leukemia, 27(3), 642-649. Nature Publishing Group
Leukemia

Donor T cells directed at hematopoietic system-specific minor histoconnpatibility antigens (mHags) are considered important cellular tools to induce therapeutic graft-versus-tumor (GvT) effects with low risk of graft-versus-host disease after allogen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::662dbade09be70cb5bd43d630d13b365
http://www.scopus.com/inward/record.url?scp=84875219394&partnerID=8YFLogxK

Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial

Autor: Fabian Termorshuizen, R. van der Griend, S. Wittebol, M. R. Schaafsma, Pieter Sonneveld, Harm Sinnige, P. W. Wijermans, H. M. Lokhorst, Silvia G. R. Verelst, Sonja Zweegman, M. van Marwijk Kooy, Rianne Ammerlaan, C.A. Uyl-de Groot

Publikováno v: Verelst, S G R, Termorshuizen, F, Uyl-de Groot, C A, Schaafsma, M R, Ammerlaan, A H M, Wittebol, S, Sinnige, H A M, Zweegman, S, Kooy, M V, van der Griend, R, Lokhorst, H M, Sonneveld, P & Wijermans, P W 2011, ' Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial ', Annals of Hematology, vol. 90, no. 12, pp. 1427-1439 . https://doi.org/10.1007/s00277-011-1224-1
Annals of Hematology, 90(12), 1427-1439. Springer Verlag
Annals of Hematology, 90(12), 1427-1439. Springer-Verlag

Abstract 2972 Thalidomide (T) with melphalan/prednisone (MPT) was defined as a standard treatment in elderly patients with multiple myeloma (MM) based on 5 randomized trials. Treatment with MPT not only showed improved response rate, significantly be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b09a70b7396dc5c9f98fb4a34a7d1de
https://doi.org/10.1007/s00277-011-1224-1

Erratum: A gene expression signature for high-risk multiple myeloma

Autor: E H van Beers, Annemiek Broyl, M. van Vliet, Y de Knegt, M. van Duin, Rowan Kuiper, G Morgan, H. M. Lokhorst, B. van der Holt, Pieter Sonneveld, W Gregory, George Mulligan, H. Goldschmidt, L el Jarari

Publikováno v: Leukemia. 28:1178-1180

Correction to: Leukemia (2012) 26, 2406–2413; doi:10.1038/leu.2012.127 Since the publication of this article, the authors have discovered an error in the script for calculating the IFM-15 risk scores. In their paper, they described the weights of a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5c8de70f8f0b1f25757c47f333f18290
https://doi.org/10.1038/leu.2014.53

Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy

Autor: M. Eurelings, J.H.J. Wokke, R. Fijnheer, H M Lokhorst, Nicolette C. Notermans, J.M.F. Niermeijer, H. Franssen

Publikováno v: Neurology, 67(11), 2076-2079. Lippincott Williams and Wilkins

We studied the efficacy of fludarabine in 16 patients with immunoglobulin M monoclonal gammopathy of unknown significance polyneuropathy in a prospective uncontrolled trial. The modified Rankin scale improved in 5/16 patients, all of whom had a demye

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::839c11fdf8f850d4f37ae828eeca2181
https://doi.org/10.1212/01.wnl.0000247671.58066.21